Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies

2.1 Tucatinib (TUKYSA, Seagen UK) has a marketing authorisation for use 'in combination with trastuzumab and capecitabine for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer who have received at least 2 prior anti-HER2 treatment regimens'.

2.2 The dosage schedule is available in the summary of product characteristics for tucatinib.

2.3 The list price is £5,636.84 per 84 pack of 150 mg film-coated tablets (excluding VAT; BNF online accessed February 2022). The average cost of a course of combination treatment at list price is £7,016.91 for the loading dose and £6,677.14 for the following cycles (company submission).

2.4 The company has a commercial arrangement. This makes tucatinib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.